10 Best Small-Cap Growth Stocks to Buy Now

5. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

3-Year Sales Growth: 45.03%

Number of Hedge Fund Holders: 23

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a biopharmaceutical company that focuses on creating treatments for people with autoimmune diseases, which are conditions where the body’s immune system mistakenly attacks its own tissues. It has developed a medicine called LUPKYNIS, which is used to treat lupus nephritis, and is also working on a new treatment called AUR200, which aims to help people with other autoimmune diseases.

During the fiscal third quarter of 2024, the company achieved $67.8 million in total net revenue, marking a 24% increase from the previous year. Notably, net product revenue was $55.5 million, up by 36% year-over-year. The growth was driven by a 25% year-over-year increase in patients on LUPKYNIS therapy. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is expanding geographically too, as LUPKYNIS has received approval in Japan. Management anticipates low double-digit royalties on net sales in Japan. It is one of the best small-cap growth stocks to buy now.